Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

MP Yadav, S Ballal, RK Sahoo… - American Journal of …, 2019 - Am Roentgen Ray Soc
OBJECTIVE. Several clinical studies have shown the efficacy of 177Lu-labeled prostate-
specific membrane antigen (PSMA) radioligand therapy (RLT) for metastatic castration …

Potential Role of 18F-FDG PET/CT in Patients With Fungal Infections

P Sharma, A Mukherjee, S Karunanithi… - American Journal of …, 2014 - Am Roentgen Ray Soc
OBJECTIVE. Combined anatomic and functional imaging with 18F-FDG PET/CT is slowly
gaining foothold in the management of various infective pathologic abnormalities. However …

[HTML][HTML] Novel radiolabeled bisphosphonates for PET diagnosis and endoradiotherapy of bone metastases

N Pfannkuchen, M Meckel, R Bergmann, M Bachmann… - Pharmaceuticals, 2017 - mdpi.com
Bone metastases, often a consequence of breast, prostate, and lung carcinomas, are
characterized by an increased bone turnover, which can be visualized by positron emission …

Prospective randomized clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinoma

C Bal, AK Padhy, S Jana, GS Pant… - … International Journal of …, 1996 - Wiley Online Library
BACKGROUND Radioiodine has been used for more than a half‐century to ablate thyroid
remnants following thyroid surgery, but a single optimal dose has not been established. We …

177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment

MP Yadav, S Ballal, M Tripathi, NA Damle… - European journal of …, 2017 - Springer
Purpose The purpose of this study was to evaluate the efficacy and safety of a novel
theranostic agent, 177 Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant …

[HTML][HTML] Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients

MP Yadav, S Ballal, RK Sahoo, M Tripathi, A Seth… - Theranostics, 2020 - ncbi.nlm.nih.gov
Rationale: Despite the success of several standards of care treatment options in metastatic
castration-resistant prostate cancer (mCRPC), a significant number of patients attain …

Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu …

S Ballal, MP Yadav, C Bal, RK Sahoo… - European journal of …, 2020 - Springer
Purpose The objective of this study was to investigate and present the early results on the
efficacy, safety, and quality of life of 225 Ac-DOTATATE targeted alpha therapy (TAT) in …

Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma

JA Sosa, R Elisei, B Jarzab, J Balkissoon, S Lu, C Bal… - Thyroid, 2014 - liebertpub.com
Background: Anaplastic thyroid cancer (ATC), a rare highly vascularized tumor, has a dismal
outcome. We conducted an open-label study of doublet carboplatin/paclitaxel chemotherapy …

The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc …

NA Damle, C Bal, GP Bandopadhyaya, L Kumar… - Japanese journal of …, 2013 - Springer
Objectives We aimed to compare the role of 18 F-fluoride PET/CT, FDG PET/CT and 99m Tc-
MDP bone scans in the detection of bone metastases in patients with lung, breast and …

Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET/CT in patients with various cancers

S Ballal, MP Yadav, ES Moon, VS Kramer… - European journal of …, 2021 - Springer
Abstract Purpose [68 Ga] Ga-labeled fibroblast activation protein inhibitors ([68 Ga] Ga-FAPi)
have shown promising preclinical and clinical results in PET imaging. The present study …